California Voters Divided in Support of Ballot Measure That Would Fund Stem Cell Research
By Kaiser Daily Women's Health Policy Report,
Kaiser Daily Women's Health Policy Report
| 08. 16. 2004
California voters are "almost evenly divided" on a ballot measure that would provide the state with nearly $3 billion in funding for human embryonic stem cell research, according to a Field Poll survey released on Sunday, Reuters reports (Reuters, 8/15). Under the measure, which will appear on the Nov. 2 ballot as Proposition 71, the California Stem Cell Research and Cures Initiative, organized by Californians for Stem Cell Research and Cures, would provide $295 million in state funds annually for 10 years to California schools, institutes and companies that conduct embryonic stem cell research. The initiative would provide grants and loans to organizations that use stem cells derived from human embryos that are less than two weeks old. The measure also would create a 29-member panel -- appointed by the governor, University of California chancellors and other officials -- that would determine allocation of the grants, which would be provided only to California organizations. If the ballot measure is successful, California would become the first state to publicly fund embryonic stem cell research, which some scientists believe...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...